This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.
Study Type
OBSERVATIONAL
Enrollment
19
Radiation then brachytherapy
Markey Cancer Center
Lexington, Kentucky, United States
Biomarker
deoxyribonucleotide levels
Time frame: 3 months posttherapy
Biomarker
HPV DNA levels
Time frame: 3 months posttherapy
Biomarker
Circulating tumor cell count
Time frame: 3 months posttherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.